Analysts have been eager to weigh in on the Healthcare sector with new ratings on Mesoblast (MESO – Research Report) and Vaxart (VXRT – Research Report). Mesoblast (MESO) Maxim Group analyst Jason McCarthy maintained a Buy rating on Mesoblast yesterday and set a price target of $10.00. The company's shares closed last Thursday at $3.02. According to TipRanks.com, McCarthy has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -23.1% and a 23.7% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Lineage Cell Therapeutics, Arrowhead Pharmaceuticals, and Madrigal Pharmaceuticals.
https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-mesoblast-meso-and-vaxart-vxrt?utm_source=advfn.com&utm_medium=referral